Stock fact sheet · data as of
Eagle Pharmaceuticals, Inc. (EGRX): fair value, margin of safety and Wheel Score
Healthcare · Drug Manufacturers - Specialty & Generic · United States · Value
Is EGRX undervalued?
EGRX has a margin of safety of 100%: the stock closed at 0.1100 on 16 Oct 2026 against a GLS average fair value of 63.57. 8 of the 8 valuation models that produced a number sit above the price. Our screens treat a discount this large as a strong starting point for a cash-secured put, not as a verdict - the fair value is a model output, and a wide gap can mean the models are missing something the market knows.
The 8 models disagree widely: Lynch gives 11.02 while 10 Cap gives 118.09. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.
The nightly engine files EGRX under Value: positive earnings at a P/E of 18 or less.
Nine valuation models for EGRX
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 90.26 | +81956% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 33.46 | +30319% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 44.46 | +40317% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 11.02 | +9921% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 65.40 | +59356% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 118.09 | +107253% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 115.28 | +104704% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 30.62 | +27735% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 1.23 | +1016% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is weak: EGRX passes 4 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is 6.3 out of 10: a ten-year record that is consistent in some of the metrics the score tracks (revenue, earnings, margins, cash flow, returns on capital) and patchy in others.
Returns on capital are moderate - ROIC 11.8%, ROE 15.3%, ROA 8.8% - with debt at 0.29 times equity and a free-cash-flow yield of 3490.8%.
Eagle Pharmaceuticals, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Product 67%, Royalty 34% (quarter Q2 FY2023).
Institutional ownership scores 1/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 4 / 9 | ROIC | 11.8% |
|---|---|---|---|
| GLS Moat | 6.3 / 10 | ROE | 15.3% |
| Debt / equity | 0.29 | ROA | 8.8% |
| Free-cash-flow yield | 3490.8% | Payout ratio | 0% |
| Institutions | 1 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 39: No options
EGRX has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (39 here). The valuation and quality numbers still apply to owning the shares outright.
Volume runs at 2k shares a day on a market cap of $1M, with a beta of 0.66 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 6 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 100% margin of safety | |
| Health | 9 / 20 | Piotroski 4/9 | |
| Moat | 9 / 15 | moat 6.3/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 6 / 20 | 2k shares/day, $1M cap, beta 0.66 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 9 Nov 2026, 24 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Drug Manufacturers - Specialty & Generic
The 12 companies below are the closest to Eagle Pharmaceuticals, Inc. by market cap within the Drug Manufacturers - Specialty & Generic industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| RDHL RedHill Biopharma Ltd. | 0.4862 | - | - | 23No options | $2M |
| PCYN Procyon Corporation | 0.2700 | 0.1965 | -37% | 15No options | $2M |
| IMCC IM Cannabis Corp. | 1.33 | - | - | 24No options | $803K |
| UPC Universe Pharmaceuticals Inc. | 4.15 | 7,380.95 | +100% | 38No options | $3M |
| AKAN Akanda Corp. | 1.31 | - | - | 19No options | $3M |
| GELS Gelteq Limited Ordinary Shares | 0.4306 | - | - | 29No options | $4M |
| YCBD cbdMD, Inc. | 0.3530 | - | - | 20No options | $4M |
| SBFM Sunshine Biopharma, Inc. | 0.2430 | - | - | 34No options | $516K |
| SNOA Sonoma Pharmaceuticals, Inc. | 1.16 | - | - | 30No options | $6M |
| INM InMed Pharmaceuticals Inc. | 1.33 | - | - | 26No options | $7M |
| CABR Caring Brands, Inc. | 1.29 | 0.1461 | -781% | 10No options | $12M |
| BIOE Bio Essence Corporation | 0.3300 | 0.8646 | +62% | 39No options | $13M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about EGRX
Is EGRX undervalued right now?
By the GLS models, yes: at 0.1100 the stock is 100% below the average fair value of 63.57 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of EGRX and what does it mean?
EGRX has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for EGRX?
63.57 per share as of 16 Oct 2026 - the simple average of the 8 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Eagle Pharmaceuticals, Inc. report earnings next?
The next earnings report is due on 9 Nov 2026, 24 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does EGRX have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on EGRX, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.